Martine Rothblatt, a director and officer of United Therapeutics Corporation, filed a Form 144 notice on November 2, 2026, proposing the sale of 119,410 shares of common stock acquired through the exercise of stock options.

Key Highlights

  • Proposed sale: 119,410 shares of United Therapeutics common stock, with an aggregate market value of $71,493,155.20, according to the filing.
  • Acquisition method: The shares were acquired on November 2, 2026, through the exercise of stock options from the issuer, with cash payment on the same date.
  • Broker named: Morgan Stanley Smith Barney LLC Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004, is listed as the broker for the proposed sale.
  • Shares outstanding: The filing reports 42,890,692 shares of common stock outstanding.
  • Prior 10b5-1 sales: The filing discloses approximately 57 prior 10b5-1 sales of 9,500 shares each conducted by Rothblatt between August 18, 2026, and October 30, 2026, on NASDAQ.
  • Filer relationship: Martine Rothblatt is identified as both a Director and an Officer of United Therapeutics Corporation (NASDAQ:UTHR).

Rothblatt's Proposed November 2026 Sale: Option Exercise and Prior Sales Activity

According to the Form 144 filing submitted to the SEC, Martine Rothblatt, identified as both a director and officer of United Therapeutics Corporation (NASDAQ:UTHR), provided notice of a proposed sale of 119,410 shares of the company's common stock. The filing states the shares were acquired on November 2, 2026, via exercise of stock options from the issuer, with payment made in cash on the same date. The aggregate market value of the proposed sale is listed as $71,493,155.20, and the approximate date of sale is given as November 2, 2026.

The filing also discloses Rothblatt's sales activity during the preceding three months under a 10b5-1 plan. According to the filing, sales of 9,500 shares each were recorded on each trading day from August 18, 2026, through October 30, 2026, with gross proceeds per transaction ranging from $4,498,752.55 (on September 24, 2026) to $5,700,855.95 (on October 30, 2026). All prior sales listed in the filing were conducted on NASDAQ and are attributed to Rothblatt at the address 1000 Spring St, Silver Spring, MD 20910, which is also listed as the issuer's address.

The filing identifies Morgan Stanley Smith Barney LLC Executive Financial Services as the named broker for the proposed transaction. The total shares of common stock outstanding are reported as 42,890,692 in the filing.

What Was Disclosed

United Therapeutics director and officer Martine Rothblatt filed a Form 144 notice proposing to sell 119,410 shares of common stock, acquired via stock option exercise on November 2, 2026, with an aggregate market value of $71,493,155.20, alongside disclosure of prior 10b5-1 plan sales.